AI in Healthcare Research: How Bionomeex Advances Genomics and Medical Imaging with Peer-Reviewed Technology

Most AI companies claim to be transforming healthcare. Few can show you a paper in Genome Biology, an active collaboration with two university hospitals, and a technology that addresses one of the fundamental unsolved problems in human genetics.

Bionomeex is a CNRS and University of Montpellier DeepTech spin-off that develops AI tools for healthcare research not for hospital administration or clinical workflow automation, but for the scientific layer that drives medical progress: genomics, medical imaging, and the genetic architecture of complex disease. This article explains what that means in practice, through the projects and technologies that define Bionomeex's work in healthcare.

The Real Frontier of AI in Healthcare The Scientific Layer

Precision healthcare is increasingly oriented toward therapeutic strategies as individualized as the patients receiving them, driven by the growing accessibility of multi-omics data including genomics, transcriptomics, proteomics, and metabolomics.

But this precision medicine future depends entirely on the quality of the scientific tools used to analyze biological data. Better genomic analysis means better biomarker discovery. Better imaging AI means faster and more accurate clinical interpretation. The limiting factor is not data volume it is analytical depth.

This is where Bionomeex operates. Not as a platform that aggregates existing AI capabilities, but as a builder of technologies that go further than what standard approaches allow specifically in genomics, where the problem of missing heritability has constrained progress for decades, and in biological imaging, where the gap between data collection and meaningful quantification remains enormous.

GWAS-2D — Addressing the Missing Heritability Problem

The central challenge in genomic medicine is not sequencing. It is interpretation. For most complex diseases cardiovascular conditions, metabolic disorders, psychiatric conditions, rare inherited syndromes individual genetic variants explain only a fraction of observed heritability. The rest is governed by interactions between variants, a phenomenon known as epistasis, which standard GWAS approaches cannot systematically explore.

AI plays a crucial role in advancing personalized medicine by identifying genetic variants linked to diseases and tailoring treatments accordingly but the standard variant-by-variant approach hits a hard ceiling on complex traits.

Bionomeex's GWAS-2D technology was built to go beyond that ceiling. By analyzing over 60 billion pairwise interactions between genetic variants in hours rather than years, it produces complete epistatic interaction maps identifying the genetic combinations that drive disease risk, trait expression, and therapeutic response at a resolution no conventional GWAS can achieve.

This technology was published in Genome Biology in March 2024 one of the most rigorous peer-review processes in biological science under the title "Next-Gen GWAS: full 2D epistatic interaction maps retrieve part of missing heritability and improve phenotypic prediction." The Luciol visualization software, developed by Bionomeex to make these interaction maps navigable, was co-funded by BPI France.

→ Read more: A Breakthrough in Genetics → What is GWAS?

Clinical Collaborations — Where the Science Meets the Hospital

CHU de Bordeaux — Complex Disease Genetics

In collaboration with the Bordeaux University Hospital (CHU de Bordeaux), Bionomeex applies its 2D-GWAS pipeline to human disease research. The collaboration focuses on identifying the epistatic genetic architecture underlying complex diseases conditions where no single genetic variant explains the observed risk, but where combinations of variants can provide clinically meaningful insight into predisposition, progression, and potential therapeutic targets.

This is not a pilot. It is an active research collaboration with one of France's leading university hospitals, applying a peer-reviewed technology to real clinical research questions.

→ Read more: 2D-GWAS in Complex Disease Research at Bordeaux University Hospital

CHU Sainte-Justine, Montreal — Advancing Genetic Disease Prediction

Bionomeex also collaborates with CHU Sainte-Justine in Montreal one of the largest mother-child university hospital centers in North America on genetic disease prediction. This collaboration applies GWAS-2D to pediatric and inherited disease genetics, where identifying epistatic interactions early can fundamentally change clinical management and family counseling.

The international dimension of this collaboration reflects the scientific reach of the technology: Bionomeex's tools are used not because they are locally convenient, but because they offer capabilities that no equivalent tool currently provides.

→ Read more: Advancing Genetic Disease Prediction

AI for Medical Imaging — From MRI to Microscopy

Beyond genomics, Bionomeex develops AI systems for biological and medical image analysis. The core capabilities detection, segmentation, quantification, and tracking are applied across multiple imaging modalities relevant to clinical and research environments.

MRI and radiology - AI models that detect and segment regions of interest in MRI, CT, and ultrasound data, reducing the time required for image interpretation and enabling more consistent, reproducible quantification across large imaging datasets.

Histology and microscopy - AI-driven segmentation and quantification of tissue samples, cell populations, and subcellular structures. Particularly relevant for pathology research, where manual analysis creates significant throughput bottlenecks.

Super-resolution microscopy (SMLM/PALM) - Bionomeex's founding technology, licensed from SATT AxLR, applies AI to numerically enhance image quality in single-molecule localization microscopy. This allows researchers to observe molecular dynamics with precision that standard acquisition conditions cannot reliably achieve.

All imaging tools are built with a Human-in-the-Loop methodology: AI predictions are continuously validated and refined by domain experts radiologists, pathologists, biologists ensuring that clinical and scientific rigor is maintained rather than traded away for automation speed.

→ Read more: AI for Medical Imaging Analysis

Why Scientific Validation Matters More Than Feature Lists

The field of AI in genomic medicine is surrounded by myths and controversies about what AI can and cannot do reliably in clinical genetics contexts. In this environment, the most important question to ask of any healthcare AI tool is not what it claims to do, but what evidence exists that it works.

Bionomeex's answer to that question is specific and verifiable. The GWAS-2D technology is published in a top-tier journal. The imaging technology originated from a formal CNRS technology transfer. The clinical collaborations are with named university hospitals. The DeepTech label from BPI France certifies that the technology stems from a genuine research breakthrough.

This matters for researchers and clinicians considering which AI tools to build their work around. A tool that produces results you cannot validate scientifically creates risk, not progress. Bionomeex builds tools designed to be validated because they were built by scientists, for scientific environments.

Frequently Asked Questions

What specific diseases does Bionomeex's genomics technology apply to? GWAS-2D is disease-agnostic it applies to any condition where complex genetic interactions are hypothesized to play a role. Current collaborations focus on complex inherited diseases (CHU de Bordeaux, CHU Sainte-Justine), but the technology has also been applied to plant genetics and population biology. The common requirement is a dataset with sufficient individuals, measured phenotypic traits, and genotype data.

How is GWAS-2D different from standard polygenic risk scores? Polygenic risk scores aggregate the additive effects of individual variants. GWAS-2D maps interactions between pairs of variants epistatic effects which are not captured by additive models. For traits where epistasis contributes significantly to heritability, this provides a meaningfully different and complementary layer of genetic information.

Can Bionomeex's imaging tools be integrated into existing clinical or research workflows? Yes. Our tools are designed to fit into existing pipelines, not replace them. We typically start by understanding the imaging modalities and data formats in use, then develop a solution that outputs results in a format compatible with your existing analysis environment.

Is patient data secure when working with Bionomeex? Data confidentiality is a contractual commitment in every engagement. We build models in your environment or in sovereign cloud infrastructure patient and research data never leaves the agreed perimeter. This is non-negotiable for clinical research, and we design our workflows accordingly.

What is the entry point for a research institution interested in working with Bionomeex? An initial conversation about your data its type, volume, and the scientific question you are trying to answer. No commitment is required at that stage. We will tell you honestly whether and how our technologies can help.

AI in Healthcare Research The Standard That Should Be Expected

Healthcare AI is a field where the gap between marketing claims and scientific reality is wide. The tools that will actually advance medicine are not those with the most polished interfaces or the broadest feature sets they are the ones that produce results that can be replicated, validated, and built upon by the scientific community.

Bionomeex was built to that standard. Its technologies are published, its collaborations are with named research institutions, and its founders are scientists who understand what rigor means in the context of human health.

If you are a researcher, clinician, or institution working with genomic or imaging data and looking for AI tools that meet scientific standards not just commercial ones we would like to hear from you.

→ Contact Bionomeex